Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-free survival (PFS) associated with their use in hormone receptor-positive, HER2-negative advanced breast cancer (BC), has radically changed the approach to managing this disease. However, resistance to CDK4/6...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Autores principales: McCartney, Amelia, Migliaccio, Ilenia, Bonechi, Martina, Biagioni, Chiara, Romagnoli, Dario, De Luca, Francesca, Galardi, Francesca, Risi, Emanuela, De Santo, Irene, Benelli, Matteo, Malorni, Luca, Di Leo, Angelo
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6664013/
https://ncbi.nlm.nih.gov/pubmed/31396487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00666
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares